593 related articles for article (PubMed ID: 24920792)
1. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model.
Wu J; Huang S; Zhao X; Chen M; Lin Y; Xia Y; Sun C; Yang X; Wang J; Guo Y; Song J; Zhang E; Wang B; Zheng X; Schlaak JF; Lu M; Yang D
J Virol; 2014 Sep; 88(18):10421-31. PubMed ID: 24920792
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous or Prior Activation of Intrahepatic Type I Interferon Signaling Leads to Hepatitis B Virus Persistence in a Mouse Model.
Zou S; Du Y; Huang S; Chen M; Yang X; Li S; Chen Y; Han M; Li J; Yu Q; Littwitz-Salomon E; Huang H; Trilling M; Liu S; Pei R; Liu J; Wang B; Zheng X; Lu M; Dittmer U; Sun S; Yang D; Wu J
J Virol; 2021 Nov; 95(24):e0003421. PubMed ID: 34550772
[TBL] [Abstract][Full Text] [Related]
3. The doses of plasmid backbone plays a major role in determining the HBV clearance in hydrodynamic injection mouse model.
Wang X; Zhu J; Zhang Y; Li Y; Ma T; Li Q; Xu J; Xu L
Virol J; 2018 May; 15(1):89. PubMed ID: 29783985
[TBL] [Abstract][Full Text] [Related]
4. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection.
Song J; Zhou Y; Li S; Wang B; Zheng X; Wu J; Gibbert K; Dittmer U; Lu M; Yang D
PLoS One; 2014; 9(3):e90977. PubMed ID: 24618716
[TBL] [Abstract][Full Text] [Related]
6. Oral administered particulate yeast-derived glucan promotes hepatitis B virus clearance in a hydrodynamic injection mouse model.
Yu X; Zhang D; Shi B; Ren G; Peng X; Fang Z; Kozlowski M; Zhou X; Zhang X; Wu M; Wang C; Yuan Z
PLoS One; 2015; 10(4):e0123559. PubMed ID: 25856080
[TBL] [Abstract][Full Text] [Related]
7. CXCL13-mediated recruitment of intrahepatic CXCR5
Li Y; Tang L; Guo L; Chen C; Gu S; Zhou Y; Ye G; Li X; Wang W; Liao X; Wang Y; Peng X; Liu G; Zhang X; Sun J; Peng J; Hou J
J Hepatol; 2020 Mar; 72(3):420-430. PubMed ID: 31610223
[TBL] [Abstract][Full Text] [Related]
8. Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo.
Leong CR; Funami K; Oshiumi H; Mengao D; Takaki H; Matsumoto M; Aly HH; Watashi K; Chayama K; Seya T
Oncotarget; 2016 Oct; 7(42):68179-68193. PubMed ID: 27626689
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance.
Lan P; Zhang C; Han Q; Zhang J; Tian Z
Hepatology; 2013 Jul; 58(1):73-85. PubMed ID: 23447417
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic and therapeutic HBV vaccination by an HBs-expressing cytomegalovirus vector lacking an interferon antagonist in mice.
Huang H; Rückborn M; Le-Trilling VTK; Zhu D; Yang S; Zhou W; Yang X; Feng X; Lu Y; Lu M; Dittmer U; Yang D; Trilling M; Liu J
Eur J Immunol; 2021 Feb; 51(2):393-407. PubMed ID: 33029793
[TBL] [Abstract][Full Text] [Related]
11. Natural killer T cell activation inhibits hepatitis B virus replication in vivo.
Kakimi K; Guidotti LG; Koezuka Y; Chisari FV
J Exp Med; 2000 Oct; 192(7):921-30. PubMed ID: 11015434
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
13. Inducible interleukin 32 (IL-32) exerts extensive antiviral function via selective stimulation of interferon λ1 (IFN-λ1).
Li Y; Xie J; Xu X; Liu L; Wan Y; Liu Y; Zhu C; Zhu Y
J Biol Chem; 2013 Jul; 288(29):20927-20941. PubMed ID: 23729669
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
Ma Z; Zhang E; Yang D; Lu M
Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B.
Li L; Shen H; Li A; Zhang Z; Wang B; Wang J; Zheng X; Wu J; Yang D; Lu M; Song J
Virol J; 2013 Jun; 10():214. PubMed ID: 23805945
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver.
Suslov A; Boldanova T; Wang X; Wieland S; Heim MH
Gastroenterology; 2018 May; 154(6):1778-1790. PubMed ID: 29408639
[TBL] [Abstract][Full Text] [Related]
17. Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression.
Kawashima K; Isogawa M; Hamada-Tsutsumi S; Baudi I; Saito S; Nakajima A; Tanaka Y
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209178
[TBL] [Abstract][Full Text] [Related]
18. The dose of HBV genome contained plasmid has a great impact on HBV persistence in hydrodynamic injection mouse model.
Li L; Li S; Zhou Y; Yang L; Zhou D; Yang Y; Lu M; Yang D; Song J
Virol J; 2017 Oct; 14(1):205. PubMed ID: 29070073
[TBL] [Abstract][Full Text] [Related]
19. Delivery of toll-like receptor 3 ligand poly(I:C) to the liver by calcium phosphate nanoparticles conjugated with an F4/80 antibody exerts an anti-hepatitis B virus effect in a mouse model.
Du Y; Yang X; Li J; Sokolova V; Zou S; Han M; Yan H; Wey K; Lu M; Dittmer U; Yang D; Epple M; Wu J
Acta Biomater; 2021 Oct; 133():297-307. PubMed ID: 33540061
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-15 suppresses hepatitis B virus replication via IFN-β production in a C57BL/6 mouse model.
Yin W; Xu L; Sun R; Wei H; Tian Z
Liver Int; 2012 Sep; 32(8):1306-14. PubMed ID: 22380514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
